New research, from a team from Imperial College London and Queen Mary University of London and published in Science, looks at the impact of how the first SARS-CoV-2 spike protein a person encounters, be it by vaccination or infection, shapes their subsequent immune response against current and future variants.
The new study involves detailed, longitudinal follow-up of the ‘Barts COVIDsortium’ healthcare worker cohort of 731 individuals, who have been followed since March 2020 and looks at the cohort after 2 doses of Pfizer vaccine to understand their immune response to infection by variants of concern.
Journalists dialled into this briefing to hear authors discuss their findings and answer questions.
Speakers will included:
Prof Danny Altmann, Professor of Immunology at Imperial College London
Prof Rosemary Boyton, Professor of Immunology and Respiratory Medicine, Imperial College London